Table 1.
Patient | Sex | Race | Age at Enrollment (y) | Diagnosis | Immunosuppressive Medications at Enrollment | Immunosuppressive Medications at Last Follow-Up | Adverse Events (Related to Study Medication)* |
---|---|---|---|---|---|---|---|
001 | M | H | 33 | Chronic NG IU | None | Efalizumab | Transient neutropenia, transient vision loss |
002 | F | C | 22 | Chronic NG IU | Pred 20 mg qd | Efalizumab | Transient ocular pain, transient skin rash |
003 | M | AA | 31 | Pars Planitis | Cell 1500 mg bid, Pred 15 mg qd, PF qid OU | Efalizumab, Cell 1500 mg bid, Pred 15 mg qd, PF qid OU | Transient lymphocytosis, URI and sore throat, transient headaches |
004 | F | C | 60 | Chronic NG IU | Cell 1000 mg bid | Efalizumab; Cell 1000 mg bid; CSA 100 mg bid | Hot flashes |
005 | M | A | 28 | VKH | Pred 5 mg qd CSA 100 mg bid AZA 50 mg qd | Efalizumab, Pred 5 mg qd, CSA 50 mg bid | Transient headaches, lymphocytosis, fatigue |
006 | F | AA | 82 | Posterior scleritis with IU | Cell 1000 mg bid, Pred 15 mg qd | Efalizumab, Cell 500 mg bid, Pred 15 mg qd | Lymphocytosis, ocular discomfort, dizziness and nausea |
H, Hispanic; C, Caucasian; AA, African American; A, Asian; NG, nongranulomatous; IU, intermediate uveitis; VKH, Vogt-Koyanagi-Harada Syndrome; Pred, Prednisone; Cell, Cellcept (Genentech, S. San Francisco, CA); PF, Prednisolone acetate 1%; CSA, cyclosporine; AZA, azathioprine; bid, twice daily; qd, daily; qid, four times a day.
Adverse events deemed related to study medication.